



Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2006

July 28, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 28, 2005--Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EDT on Thursday, August 4, 2005 to discuss the Company's financial results for its first quarter of fiscal 2006. Management will review the quarter and provide an update on the Company.

The conference call may be accessed by dialing 1-866-818-1395 for domestic callers and 1-703-639-1379 for international callers. The conference call ID number is 747574. Additionally, the call will be webcast on the investor relations section of Alkermes' website at www.alkermes.com and archived on the site until Tuesday, August 9, 2005 at 5:00pm EDT.

A replay of the conference call will be available from 7:30pm EDT on August 4, 2005 through 5:00pm EDT on August 9, 2005, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 747574.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal Consta(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag ("Janssen"), a wholly owned subsidiary of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) (naltrexone long-acting injection), is being developed as a once-monthly injection for the treatment of alcohol dependence. The Company has a pipeline of extended-release injectable products and pulmonary drug products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications

SOURCE: Alkermes, Inc.